BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 16435142)

  • 1. Trends in endocrine therapy and chemotherapy for early breast cancer: a focus on the premenopausal patient.
    Jonat W; Pritchard KI; Sainsbury R; Klijn JG
    J Cancer Res Clin Oncol; 2006 May; 132(5):275-86. PubMed ID: 16435142
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women.
    Goel S; Sharma R; Hamilton A; Beith J
    Cochrane Database Syst Rev; 2009 Oct; 2009(4):CD004562. PubMed ID: 19821328
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women.
    Sharma R; Hamilton A; Beith J
    Cochrane Database Syst Rev; 2008 Oct; (4):CD004562. PubMed ID: 18843661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimal systemic therapy for premenopausal women with hormone receptor-positive breast cancer.
    Jankowitz RC; McGuire KP; Davidson NE
    Breast; 2013 Aug; 22 Suppl 2():S165-70. PubMed ID: 24074781
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complete estrogen blockade for the treatment of metastatic and early stage breast cancer.
    Michaud LB; Buzdar AU
    Drugs Aging; 2000 Apr; 16(4):261-71. PubMed ID: 10874521
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of gonadotrophin-releasing hormone (GnRH) agonists in early and advanced breast cancer in pre- and perimenopausal women.
    Robertson JF; Blamey RW
    Eur J Cancer; 2003 May; 39(7):861-9. PubMed ID: 12706354
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Luteinizing hormone-releasing hormone agonists in premenopausal hormone receptor-positive breast cancer.
    Tan SH; Wolff AC
    Clin Breast Cancer; 2007 Feb; 7(6):455-64. PubMed ID: 17386122
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of goserelin in the treatment of breast cancer.
    Rody A; Loibl S; von Minckwitz G; Kaufmann M
    Expert Rev Anticancer Ther; 2005 Aug; 5(4):591-604. PubMed ID: 16111461
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ovarian suppression/ablation in premenopausal ER-positive breast cancer patients. Issues and recommendations.
    Pritchard KI
    Oncology (Williston Park); 2009 Jan; 23(1):27-33. PubMed ID: 19283918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer--Austrian Breast and Colorectal Cancer Study Group Trial 5.
    Jakesz R; Hausmaninger H; Kubista E; Gnant M; Menzel C; Bauernhofer T; Seifert M; Haider K; Mlineritsch B; Steindorfer P; Kwasny W; Fridrik M; Steger G; Wette V; Samonigg H;
    J Clin Oncol; 2002 Dec; 20(24):4621-7. PubMed ID: 12488405
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Navigating the Challenges of Endocrine Treatments in Premenopausal Women with ER-Positive Early Breast Cancer.
    Colleoni M; Munzone E
    Drugs; 2015 Aug; 75(12):1311-21. PubMed ID: 26177891
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Luteinizing hormone-releasing hormone analogues--the rationale for adjuvant use in premenopausal women with early breast cancer.
    Jonat W
    Br J Cancer; 1998 Sep; 78 Suppl 4(Suppl 4):5-8. PubMed ID: 9741781
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant systemic therapy for women with node-positive breast cancer. The Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer.
    CMAJ; 1998 Feb; 158 Suppl 3():S52-64. PubMed ID: 9484279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant chemotherapy in early breast cancer.
    Ejlertsen B
    Dan Med J; 2016 May; 63(5):. PubMed ID: 27127018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant endocrine therapy for premenopausal women with hormone-responsive breast cancer.
    Mathew A; Davidson NE
    Breast; 2015 Nov; 24 Suppl 2():S120-5. PubMed ID: 26255743
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New insights on the role of luteinizing hormone releasing hormone agonists in premenopausal early breast cancer patients.
    Del Mastro L; Rossi G; Lambertini M; Poggio F; Pronzato P
    Cancer Treat Rev; 2016 Jan; 42():18-23. PubMed ID: 26613834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant goserelin and ovarian preservation in chemotherapy treated patients with early breast cancer: results from a randomized trial.
    Sverrisdottir A; Nystedt M; Johansson H; Fornander T
    Breast Cancer Res Treat; 2009 Oct; 117(3):561-7. PubMed ID: 19153828
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gonadotropin-releasing hormone analogues added to adjuvant chemotherapy protect ovarian function and improve clinical outcomes in young women with early breast carcinoma.
    Recchia F; Saggio G; Amiconi G; Di Blasio A; Cesta A; Candeloro G; Rea S
    Cancer; 2006 Feb; 106(3):514-23. PubMed ID: 16388519
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant endocrine therapy of premenopausal women with early breast cancer: an overview.
    Hubalek M; Brantner C; Marth C
    Wien Med Wochenschr; 2010 Apr; 160(7-8):167-73. PubMed ID: 20473727
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The place of chemotherapy in the treatment of early breast cancer.
    Buzdar A
    Br J Cancer; 1998 Sep; 78 Suppl 4(Suppl 4):16-20. PubMed ID: 9741784
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.